Dr. Cristian Ionescu-Zanetti is Chief Technology Officer and co-founder at Fluxion Biosciences.
He is the principal inventor of Fluxion's microfluidic technology and has brought numerous products to market including the IonFlux, BioFlux, & IsoFlux Systems.
Tuesday, February 19, 2013
Cristian Ionescu-Zanetti, Chief Technology Officer and co-founder of Fluxion Biosciences presents a webinar on mutation detection in circulating tumor cells using the IsoFlux System. The detection of oncogene mutations in tumor cells has become increasingly important in the clinical management of cancer. An example is KRAS mutations that are frequently found in human cancers such as colorectal cancer (CRC) and non- small cell lung cancer. Patients displaying KRAS mutations have been shown not to respond to drugs like cetuximab. While KRAS mutation detection tests using tissue are routinely used for CRC patients about to go on therapy, the limited availability of these biopsy specimens makes it impossible to track mutational status longitudinally. Circulating tumor cells (CTCs) have shown great promise to offer longitudinal insight to metastatic disease. CTCs can be obtained from a simple blood draw that overcomes previously mentioned challenges in obtaining tissue specimens, but CTC analysis has been challenging because of the small numbers of cells recovered and thus the number of patients that produce measurable samples is limited.
Here we present mutational test results using the IsoFlux, a recently introduced instrument achieving superior CTC recovery, coupled with a highly sensitive PCR assay optimized by Fluxion for use with CTCs. Improvements in recovery resulted in a majority of patients tested presenting CTC counts above the assay’s limit of detection. This workflow provides a viable PCR-based mutational test using circulating tumor cells.